Copyright 2009-2012 BioSignia┬«, All Rights Reserved   

     

MANAGEMENT


John A. Williams
  Chairman and CEO
A seasoned businessman and entrepreneur, John has led BioSignia since 2008. He is the co-founder of several banks, including Unity Bank and First Carolina State Bank, where he served as Chairman of the Board. In addition to his work in commercial and residential land development, he was elected Edgecombe County Commissioner. John attended the Electronic Computer Programming Institute, the University of Georgia and the University of Michigan.


Gregory Rossi, CPA
  Executive Vice President, Finance and Administration
Greg is BioSignia's senior financial executive. Before joining us, he served as Corporate Controller at SpecComm International, a magazine publisher, and Corporate Accounting Manager at CardSmart Retail. Greg holds a B.A. in Accounting from North Carolina State University.


Guizhou Hu, MD, PhD
  Executive Vice President and Chief Scientific Officer
Guizhou leads BioSignia's R & D team. He is the primary inventor on the patent of our Synthesis Analysis technology and has spearheaded the development of its proprietary applications. He has been hailed as "one of the brightest young minds" by the Chinese Academy of Preventive Medicine. Guizhou earned his M.D. at Beijing Medical University. He also holds both an M.S. in nutritional toxicology and a Ph.D. in epidemiology from Cornell University. Giuzhou joined BioSignia in 1998.


Ashlee Duncan, PhD
  Senior Vice President, Product Development and Science

As a senior member of our R & D team, Ashlee is responsible for developing and refining the strategy, design, and client experience related to BioSignia's proprietary applications. She works across the organization to provide team members with the technology, operations, and process support required to deliver outstanding product lines, while identifying and acting upon opportunities to simplify and create efficiency. Prior to joining us, Ashlee was an epidemiologist in the Drug Development Sciences division of GlaxoSmithKline; she has also worked at the EPA and NIH. Ashlee received an M.S. in toxicology and a Ph.D. in epidemiology from North Carolina State University.


Mark Ruby
 Senior Vice President, Corporate Business Development and Innovation


Mark has been with BioSignia since 2002 and has extensive sales and marketing expertise in the area of healthcare predictive modeling technologies and their use in employer wellness and medical management. He has over 25 years of experience in the healthcare industry and has held senior executive sales and marketing roles with both large and small healthcare companies. Mark was formerly with Baxter Healthcare, a Fortune 500 healthcare company, where he held several sales and marketing management positions of increasing responsibility.


Michael Bryant, MD, FACS
 Medical Director
Michael S. Bryant MD FACS

As a practicing general surgeon, Dr. Bryant treats the long-term effects of chronic disease on a daily basis, making him a strong advocate for the prevention and control of such diseases. His entrepreneurial mindset, paired with a vision for preventive clinical care, lead him to establish a 600-provider regional IPA and an employer-focused wellness and medical management company.  A graduate of University of Louisville School of Medicine, Dr. Bryant brings a wealth of knowledge, experience, and expertise to BioSignia.



 

 

 

 

 

 

BioSignia, Inc. • 401 Harrison Oaks Blvd., Suite 120 • Cary, NC 27513 • (919) 933-2021 • (888) 324-6627